Journals / İstanbul Tıp Fakültesi Dergisi / 2018 / Cilt: 81 Sayı: 4

POST-THERAPY IMAGING AFTER RADIOACTIVE IODINE THERAPY FOR DIFFERENTIATED THYROID CANCER: THE CONTRIBUTION OF SPECT-CT IMAGING TO PLANAR IMAGING

DİFERANSİYE TİROİD KANSERLERİNDE RADYOAKTİF İYOT TEDAVİSİ SONRASI GÖRÜNTÜLEME: SPECT-BT GÖRÜNTÜLEMENİN PLANAR GÖRÜNTÜLEMEYE KATKISI

Duygu Has Şimşek(İSTANBUL ÜNİVERSİTESİ, İSTANBUL TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, NÜKLEER TIP ANABİLİM DALI)
Yasemin Şanlı(İSTANBUL ÜNİVERSİTESİ, İSTANBUL TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, NÜKLEER TIP ANABİLİM DALI)
Serkan Kuyumcu(İSTANBUL ÜNİVERSİTESİ, İSTANBUL TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, NÜKLEER TIP ANABİLİM DALI)
Ebru Yılmaz(İSTANBUL ÜNİVERSİTESİ, İSTANBUL TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, NÜKLEER TIP ANABİLİM DALI)
Zeynep Gözde Özkan(İSTANBUL ÜNİVERSİTESİ, İSTANBUL TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, NÜKLEER TIP ANABİLİM DALI)
Cüneyt Türkmen(İSTANBUL ÜNİVERSİTESİ, İSTANBUL TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, NÜKLEER TIP ANABİLİM DALI)
İşık Adalet(İSTANBUL ÜNİVERSİTESİ, İSTANBUL TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, NÜKLEER TIP ANABİLİM DALI)
Ayşe Mudun(İSTANBUL ÜNİVERSİTESİ, İSTANBUL TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, NÜKLEER TIP ANABİLİM DALI)
Seher Nilgün Ünal(İSTANBUL ÜNİVERSİTESİ, İSTANBUL TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, NÜKLEER TIP ANABİLİM DALI)
Pages
106–114
Publication Date
2018-12-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Overall, SPECT-CT affected therapy management in 76 patients (23.3%).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:DOI : 10.26650/IUITFD.345626 Objective : The aim of this study was to investigate the contribution of SPECT-CT to planar imaging in patients with differentiated thyroid carcinoma (DTC) following radioiodine therapy.
📊
Key Findings & Data:Materials and Methods : Post-therapy scan was performed on 325 patients (254 women, 71 men; age range 15-81 years) who were operated on for DTC and treated with radioactive iodine (100-200 mCi) therapy.
💡
Conclusion & Impact:Overall, SPECT-CT affected therapy management in 76 patients (23.3%).
🔬Design:Araştırma Makalesi
📍Scope:Comprehensive Sample
⚙️Variables:Radyoaktif · iyot · SPECT-BT

Abstract

DOI : 10.26650/IUITFD.345626 Objective : The aim of this study was to investigate the contribution of SPECT-CT to planar imaging in patients with differentiated thyroid carcinoma (DTC) following radioiodine therapy. Materials and Methods : Post-therapy scan was performed on 325 patients (254 women, 71 men; age range 15-81 years) who were operated on for DTC and treated with radioactive iodine (100-200 mCi) therapy. Whole-body planar imaging and neck–chest planar + SPECT-CT imaging were performed on all patients. Additional SPECT-CT scans were performed in other areas where suspicious findings were observed on the planar images. The iodine-positive areas on the planar images were classified as benign, equivocal, or malignant and were also reevaluated by two nuclear medicine physicians using SPECT-CT images. The final diagnosis was verified by histology, other imaging modalities, and clinical–serological follow-up. Results : Based on patient-based analysis, SPECT/CT altered the interpretation of the planar scans by detecting the following findings: additional metastatic lymph nodes in 21 (21/50) patients, lung metastases in 2 (2/10) patients, and bone metastases in 2 (2/12) patients. Furthermore, SPECT/CT confirmed that equivocal focal uptakes were benign in 83 patients and malign in 48 patients. The sensivity, specificity, positive predictive value, negative predictive value, and accuracy were 63.4%, 92.7%, 67.7%, 91.3%, and 87%, respectively, for the planar imaging and 96.8%, 100%, 100%, 99.2%, and 99.3%, respectively, for the SPECT-CT imaging. Overall, SPECT-CT affected therapy management in 76 patients (23.3%). Conclusion : SPECT-CT imaging improves diagnostic accuracy by reducing false-negative or -positive results in planar imaging in the post-therapy scan in patients with DTC. Our findings suggest that neck-thorax SPECT-CT imaging should be incorporated into the routine imaging protocol for detecting the most metastatic sites of DTC.

Özet

DOI : 10.26650/IUITFD.345626 Amaç : Bu çalışmada differansiye papiller tiroid kanseri (DTK) olan hastalarda tedavi sonrası görüntülemede SPECT-BT’nin planar görüntülemeye katkısını araştırdık. Gereç ve Yöntem : DTK tanısı ile opere olan ve radyoaktif iyot tedavisi (100-200mCi) uygulanan toplam 325 hastaya tedavi sonrası görüntüleme yapıldı (254 kadın, 71 erkek; yaş aralığı: 15-81). Tüm hastaların tüm vücut planar ile boyun-toraks bölgesinden planar + SPECT-BT görüntüleri alındı. Ek olarak planar görüntülerde şüpheli tutulum saptanan alanlardan SPECT-BT görüntüleme yapıldı. Planar görüntülemede benign, şüpheli ve malign olarak sınıflandırılan iyot pozitif alanlar iki nükleer tıp uzmanı tarafından SPECT-BT görüntüleri ile yeniden değerlendirildi. Nihai tanı histoloji, diğer görüntüleme yöntemleri, klinik-serolojik takipler ile doğrulandı. Bulgular : Hasta bazlı sonuçlara göre SPECT-BT planar görüntülemeye ek olarak 21 (21/50) hastada metastatik lenf nodları, 2 (2/10) hastada akciğer metastazları, 2 (2/12) hastada kemik metastazları tespit ederek; 83 hastada benign, 48 hastada malign olmak üzere şüpheli tutulumları açıklığa kavuşturarak planar görüntüleme yorumunu değiştirdi. Duyarlılık, özgüllük, pozitif prediktif değer, negatif prediktif değer ve doğruluk planar görüntüleme için sırasıyla %63,4, %92,7, %67,7, %91,3, %87 iken SPECT-BT için sırasıyla % 96,8, % 100, %100, %99,2 ve %99,3 olarak hesaplandı. SPECT-BT toplamda 76 hastanın (%23,3) tedavi yönetimini etkiledi. Sonuç : SPECT-BT görüntüleme, DTC hastalarında tedavi sonrası taramada planar görüntülemenin yanlış negatif/pozitif sonuçlarını azaltarak tanısal doğruluğu artırmaktadır. Sonuçlarımız DTC’nin en sık metastaz yaptığı boyun ve toraks bölgesinin değerlendirilmesinde SPECT-BT görüntülemenin rutin görüntüleme protokolüne alınmasını önermektedir.

🔖

Cite This Article

Şimşek, D. H., Şanlı, Y., Kuyumcu, S., Yılmaz, E., Özkan, Z. G., Türkmen, C., Adalet, İ., Mudun, A., Ünal, S. N. (2018). POST-THERAPY IMAGING AFTER RADIOACTIVE IODINE THERAPY FOR DIFFERENTIATED THYROID CANCER: THE CONTRIBUTION OF SPECT-CT IMAGING TO PLANAR IMAGING. İstanbul Tıp Fakültesi Dergisi, Cilt: 81 Sayı: 4, 106–114. https://ajindex.com/articles/1113723

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (28)

  1. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. Jama. 2006;295(18):2164-7.
  2. Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngology–Head & Neck Surgery. 2014;140(4):317-22.
  3. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the US, 1985‐1995. Cancer. 1998;83(12):2638-48.
  4. Randolph GW, Thompson GB, Branovan DI, Tuttle RM. Treatment of thyroid cancer: 2007—a basic review. International Journal of Radiation Oncology* Biology* Physics. 2007;69(2):S92-S7.
  5. Abraham T, Schöder H, editors. Thyroid cancer—indications and opportunities for positron emission tomography/computed tomography imaging. Seminars in nuclear medicine; 2011: Elsevier.
  6. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1-133.
  7. Burlison JS, Hartshorne MF, Voda AM, Cocks FH, Fair JR. SPECT/CT localization of oral radioiodine activity: a retrospective study and in-vitro assessment. Nucl Med Commun. 2013 Dec;34(12):1216-22. PubMed PMID: 24128897. Pubmed Central PMCID: PMC3815121.
  8. Shapiro B, Rufini V, Jarwan A, Geatti O, Kearfott KJ, Fig LM, et al., editors. Artifacts, anatomical and physiological variants, and unrelated diseases that might cause false-positive whole-body 131-I scans in patients with thyroid cancer. Seminars in nuclear medicine; 2000: Elsevier.
  9. Glazer DI, Brown RK, Wong KK, Savas H, Gross MD, Avram AM. SPECT/CT evaluation of unusual physiologic radioiodine biodistributions: pearls and pitfalls in image interpretation. Radiographics. 2013;33(2):397-418.
  10. Kohlfuerst S, Igerc I, Lobnig M, Gallowitsch H, Gomez-Segovia I, Matschnig S, et al. Posttherapeutic 131I SPECT-CT offers high diagnostic accuracy when the findings on conventional planar imaging are inconclusive and allows a tailored patient treatment regimen. European journal of nuclear medicine and molecular imaging. 2009;36(6):886.
  11. Ciappuccini R, Heutte N, Trzepla G, Rame JP, Vaur D, Aide N, et al. Postablation (131)I scintigraphy with neck and thorax SPECT-CT and stimulated serum thyroglobulin level predict the outcome of patients with differentiated thyroid cancer. Eur J Endocrinol. 2011 Jun;164(6):961-9. PubMed PMID: 21471170.
  12. Chen L, Luo Q, Shen Y, Yu Y, Yuan Z, Lu H, et al. Incremental value of 131I SPECT/CT in the management of patients with differentiated thyroid carcinoma. J Nucl Med. 2008 Dec;49(12):1952-7. PubMed PMID: 18997044.
  13. Hassan FU, Mohan HK. Clinical Utility of SPECT/CT Imaging Post-Radioiodine Therapy: Does It Enhance Patient Management in Thyroid Cancer? Eur Thyroid J. 2015 Dec;4(4):239-45. PubMed PMID: 26835427. Pubmed Central PMCID: PMC4716421.
  14. Barwick TD, Dhawan RT, Lewington V. Role of SPECT/CT in differentiated thyroid cancer. Nucl Med Commun. 2012 Aug;33(8):787-98. PubMed PMID: 22669053.
  15. Grewal RK, Tuttle RM, Fox J, Borkar S, Chou JF, Gonen M, et al. The effect of posttherapy 131I SPECT/CT on risk classification and management of patients with differentiated thyroid cancer. J Nucl Med. 2010 Sep;51(9):1361-7. PubMed PMID: 20720058.
  16. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association (ATA) guidelines taskforce on thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167-214.
  17. Edge S, Byrd D, Compton C, Fritz A, Greene F. Trotti A, editors: AJCC cancer staging manual. New York: Springer. 2010.
  18. Wong KK, Sisson JC, Koral KF, Frey KA, Avram AM. Staging of differentiated thyroid carcinoma using diagnostic 131I SPECT/CT. AJR Am J Roentgenol. 2010 Sep;195(3):730-6. PubMed PMID: 20729453.
  19. Barwick T, Murray I, Megadmi H, Drake WM, Plowman PN, Akker SA, et al. Single photon emission computed tomography (SPECT)/computed tomography using Iodine-123 in patients with differentiated thyroid cancer: additional value over whole body planar imaging and SPECT. European journal of endocrinology. 2010;162(6):1131-9.
  20. Wang H, Fu H-L, Li J-N, Zou R-J, Gu Z-H, Wu J-C. The role of single-photon emission computed tomography/computed tomography for precise localization of metastases in patients with differentiated thyroid cancer. Clinical imaging. 2009;33(1):49-54.
  21. Wong KK, Zarzhevsky N, Cahill JM, Frey KA, Avram AM. Incremental value of diagnostic 131I SPECT/CT fusion imaging in the evaluation of differentiated thyroid carcinoma. American journal of roentgenology. 2008;191(6):1785-94.
  22. Aide N, Heutte N, Rame J-P, Rousseau E, Loiseau C, Henry-Amar M, et al. Clinical relevance of single-photon emission computed tomography/computed tomography of the neck and thorax in postablation 131I scintigraphy for thyroid cancer. The Journal of Clinical Endocrinology & Metabolism. 2009;94(6):2075-84.
  23. de Pont C, Halders S, Bucerius J, Mottaghy F, Brans B. 124I PET/CT in the pretherapeutic staging of differentiated thyroid carcinoma: comparison with posttherapy 131I SPECT/CT. European journal of nuclear medicine and molecular imaging. 2013;40(5):693-700.
  24. Oh J-R, Byun B-H, Hong S-P, Chong A, Kim J, Yoo S-W, et al. Comparison of 131I whole-body imaging, 131I SPECT/CT, and 18F-FDG PET/CT in the detection of metastatic thyroid cancer. European journal of nuclear medicine and molecular imaging. 2011;38(8):1459-68.
  25. Menges M, Uder M, Kuwert T, Schmidt D. 131I SPECT/CT in the follow-up of patients with differentiated thyroid carcinoma. Clinical nuclear medicine. 2012;37(6):555-60.
  26. Salvatori M, Perotti G, Villani MF, Mazza R, Maussier ML, Indovina L, et al. Determining the appropriate time of execution of an I-131 post-therapy whole-body scan: comparison between early and late imaging. Nuclear medicine communications. 2013;34(9):900-8.
  27. Mustafa M, Kuwert T, Weber K, Knesewitsch P, Negele T, Haug A, et al. Regional lymph node involvement in T1 papillary thyroid carcinoma: a bicentric prospective SPECT/CT study. European journal of nuclear medicine and molecular imaging. 2010;37(8):1462-6.
  28. Sergieva S, Robev B. 131I SPECT-CT imaging in management of differentiated thyroid carcinoma (DTC). Journal of Nuclear Medicine. 2016;57(supplement 2):1517-.